• 1
    Reisler K. High hepatotoxicity rate seen among HAART patients. Aids Alert 2001; 16:118119. MEDLINE
  • 2
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725733. MEDLINE
  • 3
    Kaul DR, Cinti SK, Carver PL, Kazanjian PH. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19:281298. MEDLINE
  • 4
    Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, Lin JH. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996; 24:13891394. MEDLINE
  • 5
    Strassburg CP, Manns MP. Jaundice, genes and promoters. J Hepatol 2000; 33:476479. MEDLINE
  • 6
    Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:11711175. MEDLINE
  • 7
    Raijmakers MTM, Jansen PLM, Steegers EAP, Peters WHM. Association of human liver bilirubin UDP-glucuronosyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33:348351. MEDLINE
  • 8
    McPhee F, Caldera PS, Bemis GW, McDonagh AF, Kuntz ID, Craik CS. Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro. Biochem J 1996; 320:681686. MEDLINE
  • 9
    Nouts C, Bonarek M, Morlat P, Delevaux I, Bonnet F, Lacoste D, Bernard N, et al. The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir. Int J STD AIDS 2001; 12:2933. MEDLINE